Salvage chemotherapy with high-dose carboplatin and etoposide with peripheral blood stem cell transplant in patients with relapsed pure seminoma

Anuj K. Agarwala, Susan Perkins, Rafat Abonour, Mary J. Brames, Lawrence Einhorn

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: To evaluate rates of complete remission and overall survival for patients with relapsed pure seminoma treated with high-dose carboplatin and etoposide followed by peripheral blood stem cell transplant. Patients and Methods: Forty-eight consecutive patients with relapsed pure seminoma who were treated with high-dose chemotherapy (HDCT) and autologous peripheral blood stem cell transplant between May 1996 and June 2006 were retrospectively reviewed. Upon relapse (first, second, or third relapse) patients were given HDCT with carboplatin 700 mg/m and etoposide 750 mg/m for 3 consecutive days followed by infusion of peripheral blood stem cells. Here, we review both response and survival. Results: Thirty-eight (79%) of 48 patients obtained a complete response (CR) with overall survival of 75%. Median follow-up of all patients was 45.6 months. Twenty-two (92%) of 24 patients in first relapse achieved CR and are still alive and continuously disease-free. Sixteen (67%) of 24 patients had HDCT as third- or fourth-line therapy with 67% CR and overall survival of 64%. There were 3 treatment-related deaths, all of which occurred as third- or fourth-line therapy. Conclusion: HDCT results in high rates of both CR and overall survival in patients with first or later relapsed pure seminoma germ cell tumors.

Original languageEnglish
Pages (from-to)286-288
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume34
Issue number3
DOIs
StatePublished - Jun 2011

Fingerprint

Seminoma
Carboplatin
Etoposide
Transplants
Drug Therapy
Survival
Recurrence
Peripheral Blood Stem Cells
Germ Cell and Embryonal Neoplasms
Therapeutics

Keywords

  • autologous peripheral blood stem cell transplant
  • germ cell tumor
  • high-dose chemotherapy
  • relapsed pure seminoma
  • seminoma
  • testicular cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{ba9911c119bc4324947198321158fca4,
title = "Salvage chemotherapy with high-dose carboplatin and etoposide with peripheral blood stem cell transplant in patients with relapsed pure seminoma",
abstract = "Purpose: To evaluate rates of complete remission and overall survival for patients with relapsed pure seminoma treated with high-dose carboplatin and etoposide followed by peripheral blood stem cell transplant. Patients and Methods: Forty-eight consecutive patients with relapsed pure seminoma who were treated with high-dose chemotherapy (HDCT) and autologous peripheral blood stem cell transplant between May 1996 and June 2006 were retrospectively reviewed. Upon relapse (first, second, or third relapse) patients were given HDCT with carboplatin 700 mg/m and etoposide 750 mg/m for 3 consecutive days followed by infusion of peripheral blood stem cells. Here, we review both response and survival. Results: Thirty-eight (79{\%}) of 48 patients obtained a complete response (CR) with overall survival of 75{\%}. Median follow-up of all patients was 45.6 months. Twenty-two (92{\%}) of 24 patients in first relapse achieved CR and are still alive and continuously disease-free. Sixteen (67{\%}) of 24 patients had HDCT as third- or fourth-line therapy with 67{\%} CR and overall survival of 64{\%}. There were 3 treatment-related deaths, all of which occurred as third- or fourth-line therapy. Conclusion: HDCT results in high rates of both CR and overall survival in patients with first or later relapsed pure seminoma germ cell tumors.",
keywords = "autologous peripheral blood stem cell transplant, germ cell tumor, high-dose chemotherapy, relapsed pure seminoma, seminoma, testicular cancer",
author = "Agarwala, {Anuj K.} and Susan Perkins and Rafat Abonour and Brames, {Mary J.} and Lawrence Einhorn",
year = "2011",
month = "6",
doi = "10.1097/COC.0b013e3181d6b518",
language = "English",
volume = "34",
pages = "286--288",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Salvage chemotherapy with high-dose carboplatin and etoposide with peripheral blood stem cell transplant in patients with relapsed pure seminoma

AU - Agarwala, Anuj K.

AU - Perkins, Susan

AU - Abonour, Rafat

AU - Brames, Mary J.

AU - Einhorn, Lawrence

PY - 2011/6

Y1 - 2011/6

N2 - Purpose: To evaluate rates of complete remission and overall survival for patients with relapsed pure seminoma treated with high-dose carboplatin and etoposide followed by peripheral blood stem cell transplant. Patients and Methods: Forty-eight consecutive patients with relapsed pure seminoma who were treated with high-dose chemotherapy (HDCT) and autologous peripheral blood stem cell transplant between May 1996 and June 2006 were retrospectively reviewed. Upon relapse (first, second, or third relapse) patients were given HDCT with carboplatin 700 mg/m and etoposide 750 mg/m for 3 consecutive days followed by infusion of peripheral blood stem cells. Here, we review both response and survival. Results: Thirty-eight (79%) of 48 patients obtained a complete response (CR) with overall survival of 75%. Median follow-up of all patients was 45.6 months. Twenty-two (92%) of 24 patients in first relapse achieved CR and are still alive and continuously disease-free. Sixteen (67%) of 24 patients had HDCT as third- or fourth-line therapy with 67% CR and overall survival of 64%. There were 3 treatment-related deaths, all of which occurred as third- or fourth-line therapy. Conclusion: HDCT results in high rates of both CR and overall survival in patients with first or later relapsed pure seminoma germ cell tumors.

AB - Purpose: To evaluate rates of complete remission and overall survival for patients with relapsed pure seminoma treated with high-dose carboplatin and etoposide followed by peripheral blood stem cell transplant. Patients and Methods: Forty-eight consecutive patients with relapsed pure seminoma who were treated with high-dose chemotherapy (HDCT) and autologous peripheral blood stem cell transplant between May 1996 and June 2006 were retrospectively reviewed. Upon relapse (first, second, or third relapse) patients were given HDCT with carboplatin 700 mg/m and etoposide 750 mg/m for 3 consecutive days followed by infusion of peripheral blood stem cells. Here, we review both response and survival. Results: Thirty-eight (79%) of 48 patients obtained a complete response (CR) with overall survival of 75%. Median follow-up of all patients was 45.6 months. Twenty-two (92%) of 24 patients in first relapse achieved CR and are still alive and continuously disease-free. Sixteen (67%) of 24 patients had HDCT as third- or fourth-line therapy with 67% CR and overall survival of 64%. There were 3 treatment-related deaths, all of which occurred as third- or fourth-line therapy. Conclusion: HDCT results in high rates of both CR and overall survival in patients with first or later relapsed pure seminoma germ cell tumors.

KW - autologous peripheral blood stem cell transplant

KW - germ cell tumor

KW - high-dose chemotherapy

KW - relapsed pure seminoma

KW - seminoma

KW - testicular cancer

UR - http://www.scopus.com/inward/record.url?scp=79958287863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958287863&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e3181d6b518

DO - 10.1097/COC.0b013e3181d6b518

M3 - Article

VL - 34

SP - 286

EP - 288

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3

ER -